Navigation Links
Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Date:1/3/2008

598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C virus (HCV) infection and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and the belief that ANA598 is an exciting new direct antiviral to investigate for the treatment of patients with HCV infection. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies, including the animal studies described in this press release, may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2006 and Anadys' Form 10-Q for the quarter ended
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
4. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
7. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 Global cap & closure ... for caps and closures will exceed $55 billion in 2019. ... trillion annually. Beverages will continue to account for well over ... number of smaller markets are expected to register faster growth. ... the most developed markets -- the US, Western ...
(Date:4/21/2015)... Fla. , April 21, 2015  A new, ... the First Coast that promises to revolutionize the way ... fellowship-trained at the world-renowned Montsouris Institute in ... guided prostate biopsy in the North Florida ... this innovative technology in prostate cancer diagnosis and management ...
(Date:4/21/2015)... SARASOTA, Fla. , April 21, 2015   ... a drug development company focused on the treatment of ... a key independent appointment to the Company,s Board of ... Chundru Samuel as a new director. ... CEO of Rock Creek Pharmaceuticals, said, "Dr. Samuel,s experience ...
Breaking Medicine Technology:World Caps & Closures Market 2World Caps & Closures Market 3Kasraeian Urology Unveils Jacksonville's First UroNav Advanced Prostate Cancer Detection Technology 2Kasraeian Urology Unveils Jacksonville's First UroNav Advanced Prostate Cancer Detection Technology 3Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 2Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 3Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 4Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 5Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 6Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 7
(Date:4/21/2015)... 2015 The report “Sinusitis ... analysis on the therapeutic development for Sinusitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/sinusitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Sinusitis ...
(Date:4/21/2015)... April 21, 2015 Wireless Analytics, ... has been recognized by the Boston Business Journal as ... ranking was announced at a recent event celebrating the ... of the fastest-growing private companies in Massachusetts. , Wireless ... the state that recorded the fastest revenue growth from ...
(Date:4/21/2015)... April 21, 2015 QuickMedical, a ... and supplies, now represents Schiller America's ... ECGs, Stress Tests, and Vital Signs Monitors, among ... Switzerland, is a global leader in the development ... are developed in close cooperation with the world's ...
(Date:4/21/2015)... San Diego, CA (PRWEB) April 21, 2015 ... Deconstructed PACS® strategy , Visage Imaging ... Ltd. (ASX: PME), has signed a seven-year contract ... health system in Northern Florida. The deal furthers ... the university/academic hospital space, a key area of the ...
(Date:4/21/2015)... Baltimore, Maryland (PRWEB) April 21, 2015 ... air, according to the U.S. Environmental Protection Agency (EPA). ... UV rays and cigarette smoke increase the level of ... help the body eliminate these harmful toxins is to ... superfood, broccoli boasts the highest level of glucoraphanin – ...
Breaking Medicine News(10 mins):Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 2Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 3
... governments, including California as well as others in Canada ... taxpayer dollars into major motion pictures that depict smoking ... year, a University of California, San Francisco (UCSF) researcher ... PLoS Medicine , those subsidies, along with government ...
... Aug. 23 (HealthDay News) -- Researchers say boys are ... that males have been reaching sexual maturity about 2.5 ... "The reason for earlier maturity for ... disease environments are getting more favorable for it," demographer ...
... By Amanda Gardner HealthDay Reporter , ... are hospitalized fail to receive their regular medications for ... restart them when they,re discharged, researchers say. Patients ... less likely to resume their regular medication schedule after ...
... Aug. 23 (HealthDay News) -- Certain types of mental illnesses ... indicates. Men are more likely to be diagnosed with ... to develop anxiety or depression, according to the researchers. ... efforts, said the study authors, who analyzed data collected in ...
... of Nottingham are to investigate whether the therapeutic effects ... their feelings of anger, anxiety and depression. Academics ... Contemporary art gallery and local artists for the innovative ... clay could offer to young people struggling with mental ...
... (HealthDay News) -- The amount of fighting and arguing in ... a new study suggests. Ohio State University researchers looked ... 1980 to 2000. Based on how often participants said they ... middle- and high-conflict marriages. There was little change in ...
Cached Medicine News:Health News:Taxpayer film subsidies promote youth smoking 2Health News:Boys Mature Sexually Earlier Than Ever Before: Study 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 3Health News:Mental Illness Affects Women, Men Differently, Study Finds 2Health News:Modelling emotions: A potential new therapy for disturbed teenagers 2Health News:Modelling emotions: A potential new therapy for disturbed teenagers 3Health News:Couples Who Don't Fight Much Aren't Likely to Start 2
... Combination gives you the freedom ... enhanced by distributing 70% of ... hips leaving only 30% of ... shoulders. Freedom of movement enhanced ...
A simple, one-piece design eliminates seams that irritate and also extend the life of the collar. Comes with extra long Velcro closure to fit all. Also available with trim. One size fits all. Availab...
The maternity apron is a very critical protection device for the patient and the fetus....
... Special Protective Apron is made to ... a sterile gown. Uniquely it can ... field. Reaching through the back of ... released, and the protective apron will ...
Medicine Products: